|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ETS1 |
Gene summary for ETS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ETS1 | Gene ID | 2113 |
| Gene name | ETS proto-oncogene 1, transcription factor | |
| Gene Alias | ETS-1 | |
| Cytomap | 11q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P14921 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2113 | ETS1 | AEH-subject1 | Human | Endometrium | AEH | 1.69e-02 | 2.64e-01 | -0.3059 |
| 2113 | ETS1 | AEH-subject4 | Human | Endometrium | AEH | 2.04e-03 | 2.46e-01 | -0.2657 |
| 2113 | ETS1 | AEH-subject5 | Human | Endometrium | AEH | 1.65e-03 | 2.50e-01 | -0.2953 |
| 2113 | ETS1 | EEC-subject3 | Human | Endometrium | EEC | 3.60e-04 | 3.49e-01 | -0.2525 |
| 2113 | ETS1 | EEC-subject4 | Human | Endometrium | EEC | 3.68e-07 | 2.80e-01 | -0.2571 |
| 2113 | ETS1 | GSM5276934 | Human | Endometrium | EEC | 2.37e-15 | 4.52e-01 | -0.0913 |
| 2113 | ETS1 | GSM5276937 | Human | Endometrium | EEC | 7.27e-37 | 7.46e-01 | -0.0897 |
| 2113 | ETS1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.31e-02 | 7.00e-02 | -0.1869 |
| 2113 | ETS1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 5.38e-06 | 6.79e-02 | -0.1917 |
| 2113 | ETS1 | HCC2_Meng | Human | Liver | HCC | 5.83e-06 | 2.28e-02 | 0.0107 |
| 2113 | ETS1 | HCC2 | Human | Liver | HCC | 1.58e-03 | 3.03e+00 | 0.5341 |
| 2113 | ETS1 | HCC5 | Human | Liver | HCC | 5.46e-05 | 1.62e+00 | 0.4932 |
| 2113 | ETS1 | Pt13.b | Human | Liver | HCC | 6.72e-05 | 1.16e-01 | 0.0251 |
| 2113 | ETS1 | C04 | Human | Oral cavity | OSCC | 1.93e-13 | 6.05e-01 | 0.2633 |
| 2113 | ETS1 | C21 | Human | Oral cavity | OSCC | 2.20e-14 | 5.23e-01 | 0.2678 |
| 2113 | ETS1 | C30 | Human | Oral cavity | OSCC | 1.55e-09 | 6.77e-01 | 0.3055 |
| 2113 | ETS1 | C43 | Human | Oral cavity | OSCC | 4.35e-02 | -1.39e-01 | 0.1704 |
| 2113 | ETS1 | C06 | Human | Oral cavity | OSCC | 3.87e-02 | 5.48e-01 | 0.2699 |
| 2113 | ETS1 | C07 | Human | Oral cavity | OSCC | 5.36e-03 | 4.11e-01 | 0.2491 |
| 2113 | ETS1 | EOLP-1 | Human | Oral cavity | EOLP | 3.09e-11 | 4.34e-01 | -0.0202 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004578516 | Endometrium | AEH | positive regulation of cell adhesion | 96/2100 | 437/18723 | 5.50e-11 | 7.18e-09 | 96 |
| GO:004206016 | Endometrium | AEH | wound healing | 91/2100 | 422/18723 | 4.85e-10 | 4.61e-08 | 91 |
| GO:000697916 | Endometrium | AEH | response to oxidative stress | 93/2100 | 446/18723 | 1.94e-09 | 1.64e-07 | 93 |
| GO:00485119 | Endometrium | AEH | rhythmic process | 67/2100 | 298/18723 | 1.69e-08 | 1.04e-06 | 67 |
| GO:000030216 | Endometrium | AEH | response to reactive oxygen species | 54/2100 | 222/18723 | 2.54e-08 | 1.49e-06 | 54 |
| GO:006219716 | Endometrium | AEH | cellular response to chemical stress | 71/2100 | 337/18723 | 1.03e-07 | 5.05e-06 | 71 |
| GO:000166710 | Endometrium | AEH | ameboidal-type cell migration | 90/2100 | 475/18723 | 3.73e-07 | 1.57e-05 | 90 |
| GO:004254215 | Endometrium | AEH | response to hydrogen peroxide | 38/2100 | 146/18723 | 4.70e-07 | 1.92e-05 | 38 |
| GO:009013014 | Endometrium | AEH | tissue migration | 73/2100 | 365/18723 | 5.79e-07 | 2.20e-05 | 73 |
| GO:009013214 | Endometrium | AEH | epithelium migration | 72/2100 | 360/18723 | 6.90e-07 | 2.55e-05 | 72 |
| GO:004873216 | Endometrium | AEH | gland development | 83/2100 | 436/18723 | 8.62e-07 | 3.11e-05 | 83 |
| GO:00616149 | Endometrium | AEH | pri-miRNA transcription by RNA polymerase II | 20/2100 | 55/18723 | 9.36e-07 | 3.24e-05 | 20 |
| GO:001063114 | Endometrium | AEH | epithelial cell migration | 71/2100 | 357/18723 | 1.02e-06 | 3.52e-05 | 71 |
| GO:001063214 | Endometrium | AEH | regulation of epithelial cell migration | 60/2100 | 292/18723 | 2.31e-06 | 6.77e-05 | 60 |
| GO:19028939 | Endometrium | AEH | regulation of pri-miRNA transcription by RNA polymerase II | 19/2100 | 54/18723 | 3.09e-06 | 8.55e-05 | 19 |
| GO:001063410 | Endometrium | AEH | positive regulation of epithelial cell migration | 41/2100 | 176/18723 | 3.79e-06 | 1.01e-04 | 41 |
| GO:19028956 | Endometrium | AEH | positive regulation of pri-miRNA transcription by RNA polymerase II | 16/2100 | 42/18723 | 5.66e-06 | 1.41e-04 | 16 |
| GO:003459916 | Endometrium | AEH | cellular response to oxidative stress | 58/2100 | 288/18723 | 6.49e-06 | 1.58e-04 | 58 |
| GO:00075655 | Endometrium | AEH | female pregnancy | 43/2100 | 193/18723 | 7.52e-06 | 1.80e-04 | 43 |
| GO:002241115 | Endometrium | AEH | cellular component disassembly | 80/2100 | 443/18723 | 1.07e-05 | 2.45e-04 | 80 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516626 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
| hsa0421816 | Endometrium | AEH | Cellular senescence | 37/1197 | 156/8465 | 8.49e-04 | 5.52e-03 | 4.04e-03 | 37 |
| hsa05166111 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
| hsa0421817 | Endometrium | AEH | Cellular senescence | 37/1197 | 156/8465 | 8.49e-04 | 5.52e-03 | 4.04e-03 | 37 |
| hsa0421825 | Endometrium | EEC | Cellular senescence | 40/1237 | 156/8465 | 1.89e-04 | 1.68e-03 | 1.25e-03 | 40 |
| hsa0516627 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
| hsa0421835 | Endometrium | EEC | Cellular senescence | 40/1237 | 156/8465 | 1.89e-04 | 1.68e-03 | 1.25e-03 | 40 |
| hsa0516636 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
| hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
| hsa0421822 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
| hsa0521121 | Liver | HCC | Renal cell carcinoma | 51/4020 | 69/8465 | 6.76e-06 | 5.53e-05 | 3.07e-05 | 51 |
| hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
| hsa0421832 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
| hsa0521131 | Liver | HCC | Renal cell carcinoma | 51/4020 | 69/8465 | 6.76e-06 | 5.53e-05 | 3.07e-05 | 51 |
| hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
| hsa0421820 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
| hsa0521116 | Oral cavity | OSCC | Renal cell carcinoma | 51/3704 | 69/8465 | 3.30e-07 | 2.05e-06 | 1.04e-06 | 51 |
| hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
| hsa04218110 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
| hsa0521117 | Oral cavity | OSCC | Renal cell carcinoma | 51/3704 | 69/8465 | 3.30e-07 | 2.05e-06 | 1.04e-06 | 51 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ETS1 | STM | Breast | DCIS | ARID5B,SERPINE1,PLIN2, etc. | 2.25e-01 |  |
| ETS1 | KER | Cervix | N_HPV | LAMB3,TRPV3,PLOD2, etc. | 2.30e-01 |  |
| ETS1 | TUF | Colorectum | AD | CXCL1,MMP7,DNTTIP1, etc. | 1.19e-02 |  |
| ETS1 | SSC | Colorectum | AD | CXCL1,MMP7,DNTTIP1, etc. | 1.38e-03 | |
| ETS1 | CT | Colorectum | MSI-H | CXCL1,MMP7,DNTTIP1, etc. | 2.79e-02 |  |
| ETS1 | ABS | Colorectum | MSS | CXCL1,MMP7,DNTTIP1, etc. | 9.00e-02 |  |
| ETS1 | IMENT | Colorectum | MSS | CXCL1,MMP7,DNTTIP1, etc. | 6.66e-02 | |
| ETS1 | SURF | Endometrium | EEC | AKAP12,MIR4435-2HG,CYTOR, etc. | 3.68e-01 |  |
| ETS1 | AT2L | Lung | AIS | CD2,IL7R,PTPRC, etc. | 6.48e-01 |  |
| ETS1 | CD8TEXP | Pancreas | ADJ | BCL11B,IL7R,RESF1, etc. | 1.93e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ETS1 | SNV | Missense_Mutation | c.781G>C | p.Asp261His | p.D261H | P14921 | protein_coding | deleterious(0.01) | benign(0.146) | TCGA-A2-A0YC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD | |
| ETS1 | SNV | Missense_Mutation | c.313C>A | p.Gln105Lys | p.Q105K | P14921 | protein_coding | tolerated(0.32) | benign(0.041) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| ETS1 | SNV | Missense_Mutation | c.208N>T | p.Val70Phe | p.V70F | P14921 | protein_coding | tolerated(0.52) | benign(0.015) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
| ETS1 | SNV | Missense_Mutation | rs765597503 | c.761N>C | p.Leu254Pro | p.L254P | P14921 | protein_coding | deleterious(0.03) | probably_damaging(0.916) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ETS1 | SNV | Missense_Mutation | c.26N>A | p.Gly9Glu | p.G9E | P14921 | protein_coding | deleterious_low_confidence(0.04) | benign(0) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ETS1 | SNV | Missense_Mutation | novel | c.718C>A | p.Leu240Ile | p.L240I | P14921 | protein_coding | tolerated(0.33) | benign(0.018) | TCGA-EW-A1OX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| ETS1 | deletion | Frame_Shift_Del | novel | c.1409delC | p.Pro470LeufsTer120 | p.P470Lfs*120 | P14921 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| ETS1 | SNV | Missense_Mutation | c.533N>C | p.Lys178Thr | p.K178T | P14921 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| ETS1 | SNV | Missense_Mutation | c.779N>T | p.Thr260Ile | p.T260I | P14921 | protein_coding | tolerated(0.3) | benign(0) | TCGA-CM-6679-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ETS1 | SNV | Missense_Mutation | rs137970618 | c.823N>A | p.Val275Ile | p.V275I | P14921 | protein_coding | tolerated(0.36) | benign(0.102) | TCGA-G4-6307-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |